Topics
Glioblastoma | Treatment | Clinical trials | Tislelizumab (Anti PD1)
Home > Publications > Topics > Glioblastoma > Treatment > Clinical trials > Tislelizumab
Guo G, Zhang Z, Zhang J, Wang D, Xu S, Liu G, Gao Y, Mei J, Yan Z,
Zhao R, Wang M, Li T, Bu X.
Predicting
recurrent glioblastoma clinical outcome to immune
checkpoint inhibition and low-dose
bevacizumab with tumor in situ fluid
circulating tumor DNA analysis.
Cancer
Immunol Immunother. 2024 Aug 6;73(10):193. doi:
10.1007/s00262-024-03774-7. PMID:
39105794. Interventional study. ˍ